Advertisement

Endocrine

, Volume 63, Issue 1, pp 18–26 | Cite as

Effectiveness and safety of pegvisomant: a systematic review and meta-analysis of observational longitudinal studies

  • Letícia P. Leonart
  • Fernanda S. Tonin
  • Vinicius L. Ferreira
  • Fernando Fernandez-Llimos
  • Roberto PontaroloEmail author
Meta-Analysis
  • 177 Downloads

Abstract

Purpose

Acromegaly is a rare disease that often requires drug treatment to achieve control, with pegvisomant being one of the most widely used therapies. In the present paper, we aimed to obtain evidence regarding the effectiveness and safety of pegvisomant by reviewing real-world observational longitudinal studies.

Methods

A systematic review was performed with a meta-analysis of event rates (95% confidence interval (CI)) using a random effects model. Sensitivity and subgroup analyses were performed (comprehensive meta-analysis 2.0). The systematic review was performed in accordance to preferred reporting items for systematic reviews and meta-analyses, meta-analysis of observational studies in epidemiology, and Cochrane recommendations (PROSPERO register CRD 42017059880). PubMed, Scopus, Web of Science, and SciELO were used to search for literature. Observational studies in patients using pegvisomant for the treatment of acromegaly were included.

Results

Initially, 552 papers were retrieved from the databases; and 31 articles were included in the qualitative analysis and 14 in the quantitative analysis. Eight primary meta-analyses were performed. The overall rate of patients with disease control was of 60.9% (51.8–69.3%; 95% CI). When considering patients under monotherapy, the control rate was 71.7% (64.0–78.4%; 95% CI). Tumor growth was estimated in 7.3% (4.7–11.1%; 95% CI) and elevation of transaminases in 3.0% (1.7–5.2%; 95% CI).

Conclusions

The real-world data showed that the effectiveness of pegvisomant is not as high as reported in interventional studies. Acromegaly appears to be better controlled when pegvisomant is used as a monotherapy. No serious adverse events were associated with the use of pegvisomant; however, given the high cost of this drug, further studies are required.

Keywords

Acromegaly Pituitary gland Pegvisomant Meta-analysis Observational study 

Notes

Acknowledgments

The authors would like to thank the Brazilian National Counsel of Technological and Scientific Development (CNPq) and the Coordination for the Improvement of Higher Education Personnel (CAPES) for providing scholarships.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

12020_2018_1729_MOESM1_ESM.doc (256 kb)
Supplemental information

References

  1. 1.
    K. Gunawardane, T. Krarup Hansen, J. Sandahl Christiansen, J.O. Lunde Jorgensen, Normal physiology of growth hormone in adults. in L.J. De Groot, G. Chrousos, K. Dungan, K.R. Feingold, A. Grossman, J.M. Hershman, C. Koch, M. Korbonits, R. McLachlan, M. New, J. Purnell, R. Rebar, F. Singer, A. Vinik (eds.) Endotext. (South Dartmouth, MA, 2000)Google Scholar
  2. 2.
    L. Katznelson, E.R. Laws Jr., S. Melmed, M.E. Molitch, M.H. Murad, A. Utz, J.A. Wass, S. Endocrine, Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99(11), 3933–3951 (2014).  https://doi.org/10.1210/jc.2014-2700 Google Scholar
  3. 3.
    A. Colao, D. Ferone, P. Marzullo, G. Lombardi, Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr. Rev. 25(1), 102–152 (2004).  https://doi.org/10.1210/er.2002-0022 Google Scholar
  4. 4.
    S. Melmed, Acromegaly pathogenesis and treatment. J. Clin. Invest 119(11), 3189–3202 (2009).  https://doi.org/10.1172/JCI39375 Google Scholar
  5. 5.
    P. Chanson, S. Salenave, P. Kamenicky, Acromegaly. Handb. Clin. Neurol. 124, 197–219 (2014).  https://doi.org/10.1016/B978-0-444-59602-4.00014-9 Google Scholar
  6. 6.
    S. Stormann, J. Schopohl, Perspectives on investigational drugs for acromegaly. Expert Opin. Investig. Drugs 25(4), 381–384 (2016).  https://doi.org/10.1517/13543784.2016.1142530 Google Scholar
  7. 7.
    J.M. Silverstein, Need for improved monitoring in patients with acromegaly. Endocr. Connect 4(4), R59–67 (2015).  https://doi.org/10.1530/EC-15-0064 Google Scholar
  8. 8.
    S.J. Neggers, A. Muhammad, A.J. van der Lely, Pegvisomant treatment in acromegaly. Neuroendocrinology 103(1), 59–65 (2016).  https://doi.org/10.1159/000381644 Google Scholar
  9. 9.
    FDA: Pegvisomant Approval (2018), https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process. Accessed 19 July 2018
  10. 10.
    EMA: Pegvisomant Approval (2018).Google Scholar
  11. 11.
    D.J. Moore, Y. Adi, M.J. Connock, S. Bayliss, Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation. BMC Endocr. Disord. 9, 20 (2009).  https://doi.org/10.1186/1472-6823-9-20 Google Scholar
  12. 12.
    L.P. Leonart, V.L. Ferreira, F.S. Tonin, F. Fernandez-Llimos, R. Pontarolo, Medical treatments for acromegaly: a systematic review and network meta-analysis. Value Health 21(7), 874–880 (2018).  https://doi.org/10.1016/j.jval.2017.12.014 Google Scholar
  13. 13.
    P.J. Trainer, W.M. Drake, L. Katznelson, P.U. Freda, V. Herman-Bonert, A.J. van der Lely, E.V. Dimaraki, P.M. Stewart, K.E. Friend, M.L. Vance, G.M. Besser, J.A. Scarlett, M.O. Thorner, C. Parkinson, A. Klibanski, J.S. Powell, A.L. Barkan, M.C. Sheppard, M. Malsonado, D.R. Rose, D.R. Clemmons, G. Johannsson, B.A. Bengtsson, S. Stavrou, D.L. Kleinberg, D.M. Cook, L.S. Phillips, M. Bidlingmaier, C.J. Strasburger, S. Hackett, K. Zib, W.F. Bennett, R.J. Davis, Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med 342(16), 1171–1177 (2000).  https://doi.org/10.1056/NEJM200004203421604 Google Scholar
  14. 14.
    A.J. van der Lely, R.K. Hutson, P.J. Trainer, G.M. Besser, A.L. Barkan, L. Katznelson, A. Klibanski, V. Herman-Bonert, S. Melmed, M.L. Vance, P.U. Freda, P.M. Stewart, K.E. Friend, D.R. Clemmons, G. Johannsson, S. Stavrou, D.M. Cook, L.S. Phillips, C.J. Strasburger, S. Hackett, K.A. Zib, R.J. Davis, J.A. Scarlett, M.O. Thorner, Long-term treatment of acromegaly with pegvisomant, a growth hormone-receptor antagonist. Lancet 358(9295), 1754–1759 (2001)Google Scholar
  15. 15.
    S. de Lusignan, L. Crawford, N. Munro, Creating and using real-world evidence to answer questions about clinical effectiveness. J. Innov. Health Inform. 22(3), 368–373 (2015).  https://doi.org/10.14236/jhi.v22i3.177 Google Scholar
  16. 16.
    M.L. Berger, H. Sox, R.J. Willke, D.L. Brixner, H.G. Eichler, W. Goettsch, D. Madigan, A. Makady, S. Schneeweiss, R. Tarricone, S.V. Wang, J. Watkins, C. Daniel Mullins, Good practices for real-world data studies of treatment and/or comparative effectiveness: recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in healthcare decision making. Pharmacoepidemiol. Drug Saf. 26(9), 1033–1039 (2017).  https://doi.org/10.1002/pds.4297 Google Scholar
  17. 17.
    J.P.T. Higgins, G.S.: Cochrane handbook for systematic reviews of interventions, version 5.1.0. The Cochrane Collaboration (2011).Google Scholar
  18. 18.
    A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gotzsche, J.P. Ioannidis, M. Clarke, P.J. Devereaux, J. Kleijnen, D. Moher, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Br Med J 339, b2700 (2009).  https://doi.org/10.1136/bmj.b2700 Google Scholar
  19. 19.
    D.F. Stroup, J.A. Berlin, S.C. Morton, I. Olkin, G.D. Williamson, D. Rennie, D. Moher, B.J. Becker, T.A. Sipe, S.B. Thacker, Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. J Am Med Assoc 283(15), 2008–2012 (2000)Google Scholar
  20. 20.
    G.A. Wells, B. Shea, D. O’Connell, J. Peterson, V. Welch, M. Losos, P. Tugwell, The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Accessed 13 June 2018Google Scholar
  21. 21.
    T. Brue, ACROSTUDY: status update on 469 patients. Horm. Res. 71(Suppl 1), S34–S38 (2009).  https://doi.org/10.1159/000178035 Google Scholar
  22. 22.
    P.J. Trainer, ACROSTUDY: the first 5 years. Eur. J. Endocrinol. 161(Suppl 1), S19–S24 (2009).  https://doi.org/10.1530/EJE-09-0322 Google Scholar
  23. 23.
    A.J. van der Lely, B.M. Biller, T. Brue, M. Buchfelder, E. Ghigo, R. Gomez, J. Hey-Hadavi, F. Lundgren, N. Rajicic, C.J. Strasburger, S.M. Webb, M. Koltowska-Haggstrom, Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J. Clin. Endocrinol. Metab. 97(5), 1589–1597 (2012).  https://doi.org/10.1210/jc.2011-2508 Google Scholar
  24. 24.
    P.U. Freda, M.B. Gordon, N. Kelepouris, P. Jonsson, M. Koltowska-Haggstrom, A.J. van der Lely, Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY. Endocr. Pract. 21(3), 264–274 (2015).  https://doi.org/10.4158/EP14330.OR Google Scholar
  25. 25.
    N.A. Tritos, P. Chanson, C. Jimenez, D. King, P.J. Jonsson, A. Klibanski, B.M. Biller, Effectiveness of first-line pegvisomant monotherapy in acromegaly: an ACROSTUDY analysis. Eur. J. Endocrinol. 176(2), 213–220 (2017).  https://doi.org/10.1530/EJE-16-0697 Google Scholar
  26. 26.
    C.J. Strasburger, A. Mattsson, P. Wilton, F. Aydin, J. Hey-Hadavi, B.M.K. Biller, Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant. Eur. J. Endocrinol. 178(4), 321–329 (2018).  https://doi.org/10.1530/EJE-17-0996 Google Scholar
  27. 27.
    I. Schreiber, M. Buchfelder, M. Droste, K. Forssmann, K. Mann, B. Saller, C.J. Strasburger, I. German Pegvisomant, Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur. J. Endocrinol. 156(1), 75–82 (2007).  https://doi.org/10.1530/eje.1.02312 Google Scholar
  28. 28.
    C.J. Strasburger, M. Buchfelder, M. Droste, K. Mann, G.K. Stalla, B. Saller, I. German Pegvisomant, Experience from the German pegvisomant observational study. Horm. Res. 68(Suppl 5), S70–S73 (2007).  https://doi.org/10.1159/000110481 Google Scholar
  29. 29.
    M. Buchfelder, S. Schlaffer, M. Droste, K. Mann, B. Saller, K. Brubach, G.K. Stalla, C.J. Strasburger; German Pegvisomant Observational Study, The German ACROSTUDY: past and present. Eur. J. Endocrinol. 161(Suppl 1), S3–S10 (2009).  https://doi.org/10.1530/EJE-09-0350 Google Scholar
  30. 30.
    M. Buchfelder, D. Weigel, M. Droste, K. Mann, B. Saller, K. Brubach, G.K. Stalla, M. Bidlingmaier, C.J. Strasburger, Investigators of German Pegvisomant Observational Study. Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. Eur. J. Endocrinol. 161(1), 27–35 (2009).  https://doi.org/10.1530/EJE-08-0910 Google Scholar
  31. 31.
    C. Berg, S. Petersenn, H. Lahner, B.L. Herrmann, M. Buchfelder, M. Droste, G.K. Stalla, C.J. Strasburger, U. Roggenbuck, N. Lehmann, S. Moebus, K.H. Jockel, S. Mohlenkamp, R. Erbel, B. Saller, K. Mann; Investigative Group of the Heinz Nixdorf Recall Study and the German Pegvisomant Observational Study Board and Investigators, Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J. Clin. Endocrinol. Metab. 95(8), 3648–3656 (2010).  https://doi.org/10.1210/jc.2009-2570 Google Scholar
  32. 32.
    C. Urbani, C. Sardella, A. Calevro, G. Rossi, I. Scattina, M. Lombardi, I. Lupi, L. Manetti, E. Martino, F. Bogazzi, Effects of medical therapies for acromegaly on glucose metabolism. Eur. J. Endocrinol. 169(1), 99–108 (2013).  https://doi.org/10.1530/EJE-13-0032 Google Scholar
  33. 33.
    A. Bianchi, F. Valentini, R. Iuorio, M. Poggi, R. Baldelli, M. Passeri, A. Giampietro, L. Tartaglione, S. Chiloiro, M. Appetecchia, P. Gargiulo, A. Fabbri, V. Toscano, A. Pontecorvi, L. De Marinis, Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes. J. Exp. Clin. Cancer Res 32, 40 (2013).  https://doi.org/10.1186/1756-9966-32-40 Google Scholar
  34. 34.
    S. Grottoli, P. Maffei, F. Bogazzi, S. Cannavo, A. Colao, E. Ghigo, R. Gomez, E. Graziano, M. Monterubbianesi, P. Jonsson, L. De Marinis, ACROSTUDY: the Italian experience. Endocrine 48(1), 334–341 (2015).  https://doi.org/10.1007/s12020-014-0393-9 Google Scholar
  35. 35.
    S. Cannavo, F. Bogazzi, A. Colao, L. De Marinis, P. Maffei, R. Gomez, E. Graziano, M. Monterubbianesi, S. Grottoli, G. Italian Acrostudy, Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience. J. Endocrinol. Invest 38(10), 1099–1109 (2015).  https://doi.org/10.1007/s40618-015-0289-4 Google Scholar
  36. 36.
    R.S. Auriemma, L.F. Grasso, M. Galdiero, M. Galderisi, C. Pivonello, C. Simeoli, M.C. De Martino, R. Ferrigno, M. Negri, C. de Angelis, R. Pivonello, A. Colao, Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. Endocrine 55(3), 872–884 (2017).  https://doi.org/10.1007/s12020-016-0995-5 Google Scholar
  37. 37.
    M. Ragonese, S. Grottoli, P. Maffei, A. Alibrandi, M.R. Ambrosio, G. Arnaldi, A. Bianchi, S. Puglisi, M.C. Zatelli, L. De Marinis, E. Ghigo, A. Giustina, F. Maffezzoni, C. Martini, L. Trementino, S. Cannavo, How to improve effectiveness of pegvisomant treatment in acromegalic patients. J. Endocrinol. Invest. (2017).  https://doi.org/10.1007/s40618-017-0773-0
  38. 38.
    S. Chiloiro, G. Mazziotti, A. Giampietro, A. Bianchi, S. Frara, M. Mormando, A. Pontecorvi, A. Giustina, L. De Marinis, Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly. Pituitary (2018).  https://doi.org/10.1007/s11102-018-0873-7
  39. 39.
    M. Marazuela, T. Lucas, C. Alvarez-Escola, M. Puig-Domingo, N.G. de la Torre, P. de Miguel-Novoa, A. Duran-Hervada, R. Manzanares, M. Luque-Ramirez, I. Halperin, F.F. Casanueva, I. Bernabeu, Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy. Eur. J. Endocrinol. 160(4), 535–542 (2009).  https://doi.org/10.1530/EJE-08-0705 Google Scholar
  40. 40.
    M. Marazuela, A.E. Paniagua, M.D. Gahete, T. Lucas, C. Alvarez-Escola, R. Manzanares, J. Cameselle-Teijeiro, M. Luque-Ramirez, R.M. Luque, E. Fernandez-Rodriguez, J.P. Castano, I. Bernabeu, Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study. J. Clin. Endocrinol. Metab. 96(2), E251–259 (2011).  https://doi.org/10.1210/jc.2010-1742 Google Scholar
  41. 41.
    G. Sesmilo, E. Resmini, I. Bernabeu, J. Aller, A. Soto, M. Mora, A. Pico, C. Fajardo, E. Torres, C. Alvarez-Escola, R. Garcia, C. Blanco, R. Camara, S. Gaztambide, I. Salinas, C.D. Pozo, I. Castells, C. Villabona, B. Biagetti, S.M. Webb, Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study. Clin. Endocrinol. 81(6), 883–890 (2014).  https://doi.org/10.1111/cen.12440 Google Scholar
  42. 42.
    I. Bernabeu, A. Pico, E. Venegas, J. Aller, C. Alvarez-Escola, J.A. Garcia-Arnes, M. Marazuela, P. Jonsson, N. Mir, M. Garcia Vargas, A.G. Spanish, Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY. Pituitary 19(2), 127–137 (2016).  https://doi.org/10.1007/s11102-015-0691-0 Google Scholar
  43. 43.
    M. Puig-Domingo, A. Soto, E. Venegas, R. Vilchez, C. Blanco, F. Cordido, T. Lucas, M. Marazuela, R. Casany, G. Cuatrecasas, C. Fajardo, M.A. Galvez, S. Maraver, T. Martin, E. Romero, M. Paja, A. Pico, I. Bernabeu, E. Resmini; ACROCOMB study group, Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: the ACROCOMB study. Endocrinol. Nutr. 63(8), 397–408 (2016).  https://doi.org/10.1016/j.endonu.2016.05.010 Google Scholar
  44. 44.
    A.M. Ramos-Levi, I. Bernabeu, C. Alvarez-Escola, J. Aller, T. Lucas, P. de Miguel, L. Rodriguez-Canete, M.A. Sampedro-Nunez, I. Halperin, M. Puig-Domingo, M. Marazuela, Long-term treatment with pegvisomant for acromegaly: a 10-year experience. Clin. Endocrinol. 84(4), 540–550 (2016).  https://doi.org/10.1111/cen.12993 Google Scholar
  45. 45.
    E. Kuhn, L. Maione, A. Bouchachi, M. Roziere, S. Salenave, S. Brailly-Tabard, J. Young, P. Kamenicky, P. Assayag, P. Chanson, Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study. Eur. J. Endocrinol. 173(5), 693–702 (2015).  https://doi.org/10.1530/EJE-15-0500 Google Scholar
  46. 46.
    P. Chanson, T. Brue, B. Delemer, P. Caron, F. Borson-Chazot, H. Zouater, Medecins de l’Etude ACROSTUDY. Pegvisomant treatment in patients with acromegaly in clinical practice: the French ACROSTUDY. Ann. Endocrinol. 76(6), 664–670 (2015).  https://doi.org/10.1016/j.ando.2015.10.003 Google Scholar
  47. 47.
    N.G. Basavilbaso, M. Guitelman, A. Nagelberg, G. Stalldecker, A. Carabelli, O. Bruno, K. Danilowitz, M. Manavela, S. Mallea Gil, C. Ballarino, R. Guelman, D. Katz, S. Fidalgo, R. Leal, H. Fideleff, M. Servidio, D. Bruera, F. Librandi, A. Chervin, M. Vitale, A. Basso, Experience from the Argentine Pegvisomant Observational Study: preliminary data. Front. Horm. Res. 38, 42–49 (2010).  https://doi.org/10.1159/000318493 Google Scholar
  48. 48.
    M. Madsen, S. Fisker, U. Feldt-Rasmussen, M. Andreassen, L.O. Kristensen, H. Orskov, J.O. Jorgensen, Circulating levels of pegvisomant and endogenous growth hormone during prolonged pegvisomant therapy in patients with acromegaly. Clin. Endocrinol. 80(1), 92–100 (2014).  https://doi.org/10.1111/cen.12239 Google Scholar
  49. 49.
    L. Kasuki, E.O. Machado, L.L. Ogino, M.C. Coelho, C.M. Silva, L.E. Wildemberg, C.H. Lima, M.R. Gadelha, Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response. Arch. Endocrinol. Metab. 60(5), 479–485 (2016).  https://doi.org/10.1590/2359-3997000000210 Google Scholar
  50. 50.
    O. Haliloglu, E. Kuruoglu, H.M. Ozkaya, F.E. Keskin, O. Gunaldi, B. Oz, N. Gazioglu, P. Kadioglu, N. Tanriover, Multidisciplinary approach for acromegaly: a single tertiary center’s experience. World Neurosurg. 88, 270–276 (2016).  https://doi.org/10.1016/j.wneu.2015.12.092 Google Scholar
  51. 51.
    O. Karapanou, M. Tzanela, M. Christoforaki, L. Papastathopoulou, P. Moutsatsou, E. Botoula, S. Tsagarakis, Therapeutic trends and outcome of acromegaly: a single-center experience over a 40-year period. Hormones 15(3), 368–376 (2016).  https://doi.org/10.14310/horm.2002.1680 Google Scholar
  52. 52.
    L. Ferreri, R.S. Auriemma, L.F.S. Grasso, R. Pivonello, A. Colao , Efficacy and tolerability of treatment with pegvisomant in acromegaly: an overview of literature. Expert Opinion on Orphan. Drugs 3(1), 12 (2015).  https://doi.org/10.1517/21678707.2014.970171 Google Scholar
  53. 53.
    A. Giustina, G. Arnaldi, F. Bogazzi, S. Cannavo, A. Colao, L. De Marinis, E. De Menis, E. Degli Uberti, F. Giorgino, S. Grottoli, A.G. Lania, P. Maffei, R. Pivonello, E. Ghigo, Pegvisomant in acromegaly: an update. J. Endocrinol. Invest. 40(6), 577–589 (2017).  https://doi.org/10.1007/s40618-017-0614-1 Google Scholar
  54. 54.
    A.N. Paisley, P. Trainer, W. Drake, Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly. Expert Opin. Biol. Ther. 4(3), 421–425 (2004).  https://doi.org/10.1517/14712598.4.3.421 Google Scholar
  55. 55.
    E. Ghigo, B.M. Biller, A. Colao, I.A. Kourides, N. Rajicic, R.K. Hutson, L. De Marinis, A. Klibanski, Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naive to radiation and medical therapy. J. Endocrinol. Invest. 32(11), 924–933 (2009).  https://doi.org/10.3275/672310.1007/BF03345774 Google Scholar
  56. 56.
    A. Colao, R.S. Auriemma, R. Pivonello, The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly. Pituitary 19(2), 210–221 (2016).  https://doi.org/10.1007/s11102-015-0677-y Google Scholar
  57. 57.
    G. Mazziotti, A. Giustina, Effects of lanreotide SR and autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary 13(1), 60–67 (2010).  https://doi.org/10.1007/s11102-009-0169-z Google Scholar
  58. 58.
    M.J. Rousseau, J.C. Evans, Key statistical assumptions and methods in one arm meta-analyses with binary endpoints and low event rates, including a real-life example in the area of endoscopic colonic stenting. Cogent Med 4(1), 1334318 (2017).  https://doi.org/10.1080/2331205X.2017.1334318 Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Letícia P. Leonart
    • 1
  • Fernanda S. Tonin
    • 1
  • Vinicius L. Ferreira
    • 1
  • Fernando Fernandez-Llimos
    • 2
  • Roberto Pontarolo
    • 1
    Email author
  1. 1.Universidade Federal do Paraná, Graduate Program in Pharmaceutical SciencesCuritibaBrazil
  2. 2.Research Institute for Medicines (iMed.ULisboa), Department of Social Pharmacy, Faculty of PharmacyUniversidade de LisboaLisbonPortugal

Personalised recommendations